ClinicalTrials.gg
CompletedNCT05203341SAVITRIUpdated Jan 15, 2025

Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)

A Phase 2 interventional study of Placebo and NBI-1065845 in Major Depressive Disorder, sponsored by Neurocrine Biosciences. Completed at 41 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 10 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jan 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Depressive Disorder, Major by Neurocrine Biosciences — 6 open to participants now, 6 under way, 5 of them phase 3. Depressive Disorder, Major · Neurocrine Biosciences.

Enrollment
6th of 10
183 · median 192
Started
2022
the only one that year
Phase 2
3 of 10
none open now
Registered
1st of 10
by date

Among the 10 studies in Depressive Disorder, Major by Neurocrine Biosciences, this one is the 6th largest by enrollment, is the only one that started in 2022, is one of 3 in phase 2, and was the 1st registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

6 of the 10 studies in Depressive Disorder, Major by Neurocrine Biosciences are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Depressive Disorder, Major by Neurocrine Biosciences, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of NBI-1065845 compared with placebo in participants with MDD on improving symptoms of depression.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Depression
  • MDD
  • Major Depressive Disorder
  • NBI-1065845
  • Mental Disorders
  • TAK-653
  • MADRS
  • SAVITRI
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Participants must meet all of these criteria for inclusion in the study:

  1. The participant has completed written .
  2. At the time of signing the informed consent, participant must be 18 to 65 years of age, inclusive.
  3. The participant has a primary diagnosis of recurrent Major Depressive Disorder (MDD) or persistent depressive disorder.
  4. Participant must have had inadequate response to antidepressant treatment.
  5. Participant must have a Total Hamilton Depression Rating Scale-17 Item (HAMD-17) score ≥ 22 at screening.
  6. Participants currently receiving pharmacological treatment for depression must have been taking current antidepressant medication(s) for ≥8 weeks prior to screening. Subjects not currently receiving pharmacologic treatment for depression must have received the most recent antidepressant medication(s) for ≥8 weeks in the current episode of depression.
  7. Participants must be willing and able to comply with all study procedures.

Key Exclusion Criteria:

Participants will be excluded from the study if they meet any of the following criteria:

  1. Participant is pregnant or breastfeeding or plans to become pregnant during the study.
  2. Participant has an unstable medical condition or unstable chronic disease.
  3. Participant has a history of neurological abnormalities.
  4. Participant has a current or prior psychiatric disorder that was the primary focus of treatment other than MDD.
  5. The participant's depressive symptoms have previously demonstrated nonresponse to an adequate course of treatment with electroconvulsive therapy (ECT).
  6. The participant has an alcohol or substance use disorder.
  7. In the Investigator's opinion, the participant is not capable of adhering to the protocol requirements.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
183 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive placebo orally once a day.

    Drug: Placebo

  • Experimental
    NBI-1065845 Low Dose

    Participants will receive low-dose NBI-1065845 orally once a day.

    Drug: NBI-1065845

  • Experimental
    NBI-1065845 High Dose

    Participants will receive high-dose NBI-1065845 orally once a day.

    Drug: NBI-1065845

Interventions

  • DrugPlacebo

    Matching placebo tablets

  • NBI-1065845 tablets

    Also known as: TAK-653

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Total Montgomery Åsberg Depression Rating Scale (MADRS) Score at Day 28

    Time frame: Baseline, Day 28

Secondary outcomes

  1. Change from Baseline in Total MADRS Score at Day 7, Day 14, and Day 56

    Time frame: Baseline, Days 7, 14, and 56

  2. Change from Baseline in Clinical Global Impression - Severity (CGI-S) Score at Day 28 and Day 56

    Time frame: Baseline, Days 28 and 56

  3. Response, defined as ≥50% decrease in MADRS from baseline, at Day 28 and Day 56

    Time frame: Baseline, Days 28 and 56

  4. Remission, defined as MADRS ≤10, at Days 28 and 56

    Time frame: Days 28 and 56

  5. Change from Baseline in Patient Health Questionnaire-9 (PHQ-9) Score at Day 28 and Day 56

    Time frame: Baseline, Days 28 and 56

07

Study locations

41 sites
  • Neurocrine Clinical Site
    Birmingham, Alabama 35249, United States
  • Neurocrine Clinical Site
    Huntsville, Alabama 35801, United States
  • Neurocrine Clinical Site
    Riverside, California 92506, United States
  • Neurocrine Clinical Site
    San Diego, California 92103, United States
  • Neurocrine Clinical Site
    San Francisco, California 94143, United States
  • Neurocrine Clinical Site
    Torrance, California 90502, United States
  • Neurocrine Clinical Site
    Hartford, Connecticut 06106, United States
  • Neurocrine Clinical Site
    Palmetto Bay, Florida 33158, United States
  • Neurocrine Clinical Site
    Gaithersburg, Maryland 20877, United States
  • Neurocrine Clinical Site
    Weldon Spring, Missouri 63304, United States
  • Neurocrine Clinical Site
    Columbus, Ohio 43221, United States
  • Neurocrine Clinical Site
    North Canton, Ohio 44720, United States
  • Neurocrine Clinical Site
    Oklahoma City, Oklahoma 73112, United States
  • Neurocrine Clinical Site
    Memphis, Tennessee 38119, United States
  • Neurocrine Clinical Site
    Dallas, Texas 75390, United States
  • Neurocrine Clinical Site
    Houston, Texas 77030, United States
  • Neurocrine Clinical Site
    Draper, Utah 84020, United States
  • Neurocrine Clinical Site
    Plovdiv, 4004, Bulgaria
  • Neurocrine Clinical Site
    Ruse, 7003, Bulgaria
  • Neurocrine Clinical Site
    Sofia, 1113, Bulgaria
  • Neurocrine Clinical Site
    Tsarev Brod, 9747, Bulgaria
  • Neurocrine Clinical Site
    Varna, 9020, Bulgaria
  • Neurocrine Clinical Site
    Veliko Tarnovo, 5000, Bulgaria
  • Neurocrine Clinical Site
    Vratsa, 3000, Bulgaria
  • Neurocrine Clinical Site
    Kladno, 27201, Czechia
  • Neurocrine Clinical Site
    Plzen, 30100, Czechia
  • Neurocrine Clinical Site
    Praha 10, 100 00, Czechia
  • Neurocrine Clinical Site
    Praha 6, 160 00, Czechia
  • Neurocrine Clinical Site
    Praha 8, 186 00, Czechia
  • Neurocrine Clinical Site
    Bełchatów, 97-400, Poland
  • Neurocrine Clinical Site
    Chełmno, 86-200, Poland
  • Neurocrine Clinical Site
    Gdańsk, 80-546, Poland
  • Neurocrine Clinical Site
    Katowice, 40568, Poland
  • Neurocrine Clinical Site
    Košice, 04191, Slovakia
  • Neurocrine Clinical Site
    Rimavská Sobota, 97901, Slovakia
  • Neurocrine Clinical Site
    Trenčín, 91101, Slovakia
  • Neurocrine Clinical Site
    Vranov Nad Topľou, 09301, Slovakia
  • Neurocrine Clinical Site
    Göteborg, 41650, Sweden
  • Neurocrine Clinical Site
    Halmstad, 30248, Sweden
  • Neurocrine Clinical Site
    Lund, 22222, Sweden
  • Neurocrine Clinical Site
    Stockholm, 11329, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Jan 2024, 22 months.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 22 months is above that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2021
First posted
Jan 24, 2022
StartActual
Feb 21, 2022
Primary completionActual
Jan 10, 2024
CompletionActual
Feb 21, 2024
Results delay requested
Jan 9, 2025
Last update
Jan 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05203341
Responsible party
Sponsor
First posted
Jan 24, 2022
Start date
Feb 21, 2022
Primary completion
Jan 10, 2024
Completion
Feb 21, 2024
Last update
Jan 15, 2025

Study contacts

Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osavampator

Start the discussion